UniQure tumbles with latest data for Huntington’s gene therapy

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 29 Sept, 15:36 UTC

Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."